Clinical trials

  • FENFLURAMINE HYDROCHLORIDE for CDKL5 deficiency disorder
  • OBINUTUZUMAB for Lupus nephritis (Class III or IV)
  • JNJ-87704916 for Advanced solid tumors
  • Belantamab mafodotin for Relapsed/Refractory multiple myeloma
  • RIVAROXABAN for End-stage renal disease|Chronic hemodialysis
  • FERRIC CARBOXYMALTOSE for Acute coronary syndrome
  • BNT314 for Advanced or metastatic malignant solid tumors
  • TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL for Axial spondyloarthritis
  • CANDESARTAN for Chronic cluster headache
  • Doxorubicin hydrochloride for Aggressive B-cell lymphoma | Diffuse large B-cell lymphoma | High-grade B-cell lymphoma | Primary mediastinal B-cell lymphoma | Primary cutaneous diffuse large B-cell lymphoma, leg type | Intravascular large B-cell lymphoma | Follicular lymphoma grade 3B | Lymphomatoid granulomatosis grade 3 | Mediastinal gray-zone lymphoma | Primary testicular diffuse large B-cell lymphoma | Primary effusion lymphoma (HHV-8 and EBV-negative) | EBV-positive diffuse large B-cell lymphoma | T-cell/histiocyte-rich large B-cell lymphoma | Large B-cell lymphoma with 11q aberration | High-grade B-cell lymphoma with MYC and BCL2 or MYC and BCL6 rearrangements
  • ALXN1850 for Hypophosphatasia
  • ECI830 for Hormone receptor positive HER2 negative breast cancer|Advanced solid tumors